Insider Trading Alert - Biogen Idec And 4 Others Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 2, 2013, 110 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $27.14 to $240,355,139.71.

Highlighted Stocks Traded by Insiders:

Biogen Idec (BIIB) - FREE Research Report

Scangos George A who is Chief Executive Officer at Biogen Idec sold 2,239 shares at $242.85 on Oct. 2, 2013. Following this transaction, the Chief Executive Officer owned 41,283 shares meaning that the stake was reduced by 5.14% with the 2,239 share transaction.

Schenk Lynn who is Director at Biogen Idec sold 1,000 shares at $242.85 on Oct. 2, 2013. Following this transaction, the Director owned 6,100 shares meaning that the stake was reduced by 14.08% with the 1,000 share transaction.

DiPietro Kenneth who is EVP Human Resources at Biogen Idec sold 1,440 shares at $242.00 on Oct. 2, 2013. Following this transaction, the EVP Human Resources owned 0 shares meaning that the stake was reduced by 100% with the 1,440 share transaction.

The shares most recently traded at $243.02, up $1.02, or 0.42% since the insider transaction. Historical insider transactions for Biogen Idec go as follows:

  • 4-Week # shares sold: 4,401
  • 12-Week # shares sold: 15,486
  • 24-Week # shares sold: 54,524

The average volume for Biogen Idec has been 1.2 million shares per day over the past 30 days. Biogen Idec has a market cap of $57.9 billion and is part of the health care sector and drugs industry. Shares are up 66.39% year to date as of the close of trading on Wednesday.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. The company has a P/E ratio of 36.1. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Biogen Idec Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire